Search results
Results from the WOW.Com Content Network
Myeloproliferative neoplasms (MPNs) are a group of rare blood cancers in which excess red blood cells, white blood cells or platelets are produced in the bone marrow. Myelo refers to the bone marrow , proliferative describes the rapid growth of blood cells and neoplasm describes that growth as abnormal and uncontrolled.
Multiple myeloma is the result of a multi-step malignant transformation, and almost universally originates from the pre-malignant stage monoclonal gammopathy of undetermined significance (MGUS). As MGUS evolves into MM, another pre-stage of the disease is reached, known as smoldering myeloma (SMM) .
Myelodysplastic–myeloproliferative diseases are a category of hematological malignancies which have characteristics of both myelodysplastic and myeloproliferative conditions. [1] When a hematological malignancy is characterised by normal differentiation of cells of myeloid cell line, it is referred to as myeloproliferative.
Hematological malignancies are malignant neoplasms ("cancer"), and they are generally treated by specialists in hematology and/or oncology. In some centers "hematology/oncology" is a single subspecialty of internal medicine while in others they are considered separate divisions (there are also surgical and radiation oncologists).
In hematology, essential thrombocythemia (ET) is a rare chronic blood cancer (myeloproliferative neoplasm) characterised by the overproduction of platelets (thrombocytes) by megakaryocytes in the bone marrow. [3] It may, albeit rarely, develop into acute myeloid leukemia or myelofibrosis. [3]
Primary myelofibrosis (PMF) is a rare bone marrow blood cancer. [1] It is classified by the World Health Organization (WHO) as a type of myeloproliferative neoplasm, a group of cancers in which there is activation and growth of mutated cells in the bone marrow. This is most often associated with a somatic mutation in the JAK2, CALR, or MPL genes.
The American Cancer Society estimates that in 2014, about 5,980 new cases of chronic myeloid leukemia were diagnosed, and about 810 people died of the disease. This means that a little over 10% of all newly diagnosed leukemia cases will be chronic myeloid leukemia. The average risk of a person getting this disease is 1 in 588.
A myeloid sarcoma (chloroma, granulocytic sarcoma, [1]: 744 extramedullary myeloid tumor) is a solid tumor composed of immature white blood cells [2] called myeloblasts. A chloroma is an extramedullary manifestation of acute myeloid leukemia ; in other words, it is a solid collection of leukemic cells occurring outside of the bone marrow .